Quick Answer
A clear guide to the tests that diagnose AML and the genetic findings that guide treatment.
Medically reviewed by Dr. Sachita Baniya • NMC 20158 • Kathmandu Neurology Clinic & Cognitive Center
Acute myeloid leukemia (AML) is a cancer of immature myeloid cells. It develops when genetic changes block normal maturation, so blasts accumulate in the marrow and healthy blood production fails. Diagnosis is not a single test — it is a sequence of investigations that together define the subtype, risk and treatment.
Step 1: blood counts and smear
AML is often suspected when a blood count shows anaemia, low platelets or a high white cell count, and the peripheral smear shows immature cells. A blast count on the blood can be suggestive, but a bone marrow examination is usually needed.
Step 2: bone marrow examination
A bone marrow aspiration and biopsy assess cellularity, the percentage of blasts and the presence of abnormal cells. The biopsy also shows how the marrow architecture is disturbed. The procedure is performed under local anaesthetic, usually from the back of the hip bone.
Step 3: flow cytometry
Flow cytometry identifies the lineage and maturation of the abnormal cells. It distinguishes myeloid from lymphoid leukemia, detects aberrant marker expression and helps classify the subtype. It is also used later to measure measurable residual disease.
Step 4: cytogenetics and molecular testing
Chromosomal analysis and molecular panels identify changes such as translocations, NPM1, FLT3, IDH1/2, CEBPA and TP53 mutations. These findings are central to risk stratification. Some mutations predict response to targeted drugs; others identify high-risk disease where transplant should be considered early.
Step 5: baseline fitness
Before treatment, cardiac, kidney, liver and lung function are assessed, along with infection screening and fertility counselling. Treatment intensity is matched to the patient's fitness as well as the disease risk.
What the results mean
The team combines the subtype, genetic risk, patient age and fitness to recommend induction and consolidation. A favourable-risk AML may be treated with chemotherapy alone; high-risk disease may need allogeneic transplant. MRD testing after treatment refines these decisions.
Questions to ask
- What is the exact subtype and genetic risk group?
- What is the goal of induction treatment?
- Will I be assessed for a transplant?
- Which tests will monitor response, and when?
- What warning signs should prompt urgent review?
AML treatment is intensive, and the first weeks are critical. A clear understanding of the diagnosis and plan helps patients and families participate in decisions and prepare for the treatment journey.
Frequently asked questions
Answers reviewed by Dr. Jitendra Prasad Yadav • MBBS, MD (Internal Medicine), FICN (Neurology), FCNV, FIHM • NMC 8029
AML can be cured in a proportion of patients, particularly younger adults who achieve remission and proceed to appropriate consolidation or transplant. Outcomes vary widely with genetic subtype, age and fitness, so the treating team discusses prognosis for the individual case rather than giving a single figure.
Induction is the first phase of treatment, aiming to clear leukemia cells from the marrow and restore normal blood production. It usually requires hospital admission and close support with transfusion, infection prevention and monitoring.
No. Some patients remain stable for years, while others progress. Risk depends on marrow blasts, cytogenetics, molecular findings and blood counts.
The Revised International Prognostic Scoring System estimates survival and progression risk using blasts, cytogenetics and cytopenias. It guides treatment intensity.
More: All FAQs → · Ask Dr. Jitendra →
Related articles
MDS: When Low Blood Counts Are a Marrow Problem
Myelodysplastic syndromes cause low blood counts and a variable risk of leukemia. Learn how MDS is diagnosed and treated.
Measurable Residual Disease: Why 'No Blasts Seen' Is Not Always Remission
MRD testing can detect cancer cells below the limit of microscopy. Learn how it guides treatment in leukemia and myeloma.
Blood Cancer Symptoms: When to See a Haematologist
Unexplained bruising, persistent fatigue, swollen lymph nodes or repeated infections can be early signs of a blood disorder. Here is when to seek a haematology opinion.
Medical Disclaimer
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
References & Review
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
- International Classification of Headache Disorders, 3rd edition (ICHD-3).
- Harrison's Principles of Internal Medicine — Neurology sections.
- American Academy of Neurology guidelines for selected conditions (where applicable).
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.